Physician profile
Michael T Uselton
NPI 1659332625
$1,246.76
in general payments reported to CMS, 2019-2025
23 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $109 · 2021: $91.33 · 2022: $156 · 2023: $324 · 2024: $125 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $357.84 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $142.51 | 2019-2023 | Shingrix, Arexvy |
| Pfizer INC. | $78.87 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $75.09 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.48 | 2019-2024 | Jardiance |
| Abbott Laboratories | $63.96 | 2019-2023 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $52.04 | 2019-2020 | |
| Amgen INC. | $51.62 | 2019-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $46.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $34.65 | 2019-2020 | |
| Astellas Pharma US INC | $30.54 | 2023-2025 | Veozah |
| Allergan, INC. | $27.60 | 2020 | |
| Boston Scientific Corporation | $25.88 | 2025 | Ams 700 |
| Novo Nordisk INC | $25.43 | 2019-2021 | |
| Insulet Corporation | $25.33 | 2022-2023 | Omnipod |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $23.73 | 2023 | Afrezza |
| Lilly USA, LLC | $19.88 | 2022 | |
| Dexcom, INC. | $19.33 | 2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.03 | 2022 | |
| Echosens North America, INC. | $15.51 | 2025 | Fibroscan |
| Sanofi Pasteur INC. | $14.46 | 2019 | |
| Genentech USA, INC. | $12.20 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Uselton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.